| Followers | 4045 |
| Posts | 152972 |
| Boards Moderated | 3 |
| Alias Born | 08/05/2009 |
Tuesday, March 28, 2023 1:13:06 PM
Recent BMEA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:05 PM
- Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies • GlobeNewswire Inc. • 03/31/2026 11:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/24/2026 08:12:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 08:09:28 PM
- Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 • GlobeNewswire Inc. • 03/14/2026 08:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:05:19 AM
- Biomea Fusion to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/19/2026 12:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/12/2026 09:02:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/14/2026 09:02:51 PM
- Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones • GlobeNewswire Inc. • 01/12/2026 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/06/2026 09:01:40 PM
- Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/17/2025 12:00:00 PM
- Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 • GlobeNewswire Inc. • 12/09/2025 11:35:22 PM
- Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) • GlobeNewswire Inc. • 12/05/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2025 09:15:03 PM
- Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) • GlobeNewswire Inc. • 12/01/2025 09:10:00 PM
- Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/01/2025 09:05:00 PM
- Biomea Fusion to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Biomea Fusion to Participate at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/10/2025 12:00:00 PM
- Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025 • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2025 09:09:19 PM

